Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Eli Lilly ($LLY) announced results from a second Phase 3 clinical trial assessing its lasmiditan for the acute treatment of migraine, which met its primary endpoint. The results were consistent with the first Phase 3, SAMURAI, reported about a year ago. At two hours post dose, all three (50 mg, 100 mg and 200 mg) tested doses showed a statistically significantly greater proportion of patients to be migraine-free compared to placebo. Eli Lilly plans to submit its U.S. marketing application in second half of 2018. The company had acquired the rights to the drug candidate through its acquisition of CoLucid.
Eli Lilly stock is currently trading 11 percent up on Year to Date basis.

Ritter Pharmaceuticals ($RTTR) stock shot up as the company announced the results from an additional analysis of its Phase 2b/3 clinical trial evaluating lead candidate RP-G28 in people with lactose intolerance. The company reported that the additional data showed a clear treatment effect with positive reductions in key symptoms of LI. The data also showed positive safety profile and no serious adverse events related to the treatment were observed. The drug has the potential to become the first FDA approved drug for the indication.
The stock reacted positively to the news and jumped over 7 percent in its previous trading session, trimming its YTD losses to 77 percent.

 

vTv Therapeutics ($VTVT) announced receiving a new patent pertaining methods of treatment using azeliragon for mild Alzheimer's disease (AD), specifically by administering ~5 mg per day of azeliragon. The patent No. 9,717,710 ('710 patent) has been awarded by the USPTO. The patent will remain in effect until 2034.
Aclaris Therapeutics ($ACRS) announced filing its Marketing Authorization Application (MAA) in Europe seeking approval for A-101 40% Topical Solution for the treatment of seborrheic keratosis. A-101 is a proprietary topical solution formulation of high-concentration hydrogen peroxide.

Jazz Pharmaceuticals ($JAZZ) announced receiving the FDA approval for its Vyxeos (cytarabine and daunorubicin) for the treatment of newly diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes. The drug had Breakthrough Therapy status and Orphan drug status.
Roche ($RHHBY) reported that the FDA has accepted its supplemental New Drug Application (sNDA) seeking approval for Alecensa (alectinib) for the first-line treatment of anaplastic lymphoma inase (ALK)-positive locally advanced/metastatic non-small cell lung cancer. The action date has been set at November 30.

 

RTI Surgical ($RTIX) announced selling its cardiothoracic closure unit to A&E Advanced Closure Systems, LLC for $54 million in cash plus an additional $6 million in contingent cash consideration. The company had bought the business in July 2013 in the Pioneer Surgical Technology.

Mallinckrodt ($MNK) announced inking a new deal to acquire InfaCare Pharmaceuticals. The company develops drugs for neonatal and pediatric conditions. The deal provides for the payment of $80 million upfront while up to $345 million is payable in milestone payments.

Brokerage Action Company Rating Price Target Impact on Share Price Actions
Royal Bank Of Canada Raises Target Aetna (AET)
Outperform -> Outperform $162.00 -> $171.00 Low

HC Wainwright Set Price Target Alimera Sciences (ALIM)
Buy $5.00 Low

Oppenheimer Holdings Initiates BioLineRx (BLRX)
Outperform $3.00 Low

BMO Capital Markets Reiterates bluebird bio (BLUE)
Buy $108.00 Low

HC Wainwright Set Price Target Cara Therapeutics (CARA)
Buy $30.00 High

Deutsche Bank AG Reiterates ConforMIS (CFMS)
Buy -> Hold Low

Gainers (% price change)Last TradeChangeMkt CapOraSure Tech., Inc.OSUR20.15+2.88 (16.68%)1.16BPacific Biosciences ofPACB3.66+0.46 (14.38%)398.79MBioTime, Inc.BTX2.82+0.25 (9.73%)312.67MVanda Pharmaceuticals IncVNDA16.60+1.15 (7.44%)739.57MTeleflex IncorporatedTFX216.88+13.87 (6.83%)9.76BLosers (% price change)Teva PharmaceuticalTEVA23.75-7.50 (-24.00%)24.10BPsychemedics Corp.PMD21.24-4.60 (-17.80%)115.98MEndologix, Inc.ELGX4.35-0.51 (-10.49%)360.94MAmerisourceBergen Corp.ABC81.71-9.56 (-10.47%)17.84BCytokinetics, Inc.CYTK13.50-1.50 (-10.00%)657.14MMost Actives (dollar volume)Teva PharmaceuticalTEVA23.75-7.50 (-24.00%)24.10BPfizer Inc.PFE33.43+0.51 (1.55%)199.08BGilead Sciences, Inc.GILD74.37-1.47 (-1.94%)97.18BAmerisourceBergen Corp.ABC81.71-9.56 (-10.47%)17.84BHumana IncHUM248.84+7.75 (3.21%)35.91B